🩸🧬Happy to share this @ForesightDx release ahead of #ASH24 on our MRD-guided study for newly diagnosed DLBCL is now open at @columbiacancer! The overall goal is to de-escalate cytotoxic chemotherapy for early molecular responders #lymsm #mrd
clinicaltrials.gov/study/NCT06693…
clinicaltrials.gov/study/NCT06693…
We are pleased to share that our Foresight CLARITY #MRD test will be used in @ColumbiaMed's SHORTEN-ctDNA trial, which aims to evaluate the ability to utilize MRD detection to enable real-time treatment optimization for patients with #DLBCL. hubs.li/Q02-y31N0View quoted post on X